TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies. - Burris, Howard; Kurkjian, C.; Hart, L.; Pant, S.; Murphy, P.; Jones, S.; Neuwirth, R.; Patel, C.; Zohren, F.; Infante, J.; Burris, Howard A 3rd; Kurkjian, C D; et al. (Cancer Chemotherapy & Pharmacology, 2017)